Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245194 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL1351011 | 0.79 | LATS1 (0.37) | CYP1A2CYP2C9CYP2C19HTTCTSL | |
| SCHEMBL4675685 | 0.76 | CYP1A2 (0.39) | CYP1A2CYP2C9CYP2C19HTTCTSL | |
| SCHEMBL7229743 | 0.76 | CTSS (0.47) | TSHRKMT2ACTSK | |
| SCHEMBL464420 | 0.75 | PSMB5 (0.50) | CTSLCTSKCA1CA2CA7 | |
| SCHEMBL28574603 | 0.75 | CA12 (0.43) | CTSLGHSRMAPTTSHRKMT2A | |
| SCHEMBL4674233 | 0.74 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19HTTCTSL | |
| SCHEMBL4101793 | 0.73 | GHSR (0.35) | CTSLGHSRRETMEN1KMT2A | |
| SCHEMBL583634 | 0.73 | KMT2A (0.38) | CYP1A2CYP2C9CYP2C19HTTCTSL | |
| SCHEMBL3824730 | 0.72 | GRN (0.39) | CTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419636-B2 | Vapor sensing instruments for ultra trace chemical detection | NOMADICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095058-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | GLS2, SLC10A1, UGT1A1 | CYP1A2 35/4885CYP2C9 406/4885CYP2C19 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.